RNA Clinical Trials Videos
-
Mitigating Financial Risk Before Selecting An Outsourcing Vendor
9/25/2023
Gain insight from several clinical operations experts into the significance of meticulous contract examination when choosing an outsourcing partner.
-
ICH E6(R3): Practical Steps For Implementation
12/14/2023
Watch this presentation to equip stakeholders with actionable strategies and a comprehensive understanding of the evolving clinical trial management landscape in the context of ICH guidelines.
-
Achieving mRNA-LNP Delivery Beyond The Liver
11/28/2022
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
-
Precision ADVANCE: Unravelling The Complexity Of CGTx Development
10/12/2021
Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.
-
How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today?
5/10/2024
The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.
-
Designing Effective Multivalent mRNA Therapies: Key Regulatory Considerations
6/24/2025
How many mRNAs are too many in a multivalent therapy? In this clip, Eliquent Life Science’s Tiffany Lucas and CureVac’s Ulrike Jägle delve into this question, emphasizing the factors that are essential for regulatory success and patient benefit.
-
RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati
11/21/2022
Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker — the capacity to manufacture RNA in-house. If you're curious about the expanding science behind RNA-based therapeutics and their application in biotech, this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode.
-
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino
9/11/2024
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.
-
Michelangelo Meets mRNA | ARW on RNA Ep04
5/4/2023
Hosted by Cell & Gene Collaborative's Director Anna Rose Welch, ARW on RNA puts a creative spin on the emerging mRNA + RNA therapeutics industry. Here, in Episode 4, Welch explores the parallels that exist between the oft-overlooked history of Michelangelo's David and the mRNA therapeutics sector's own R&D history, as well as where the mRNA space hopes to move in the future.
-
The Scientific Underpinnings Of mRNA/LNPs
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.